Zobrazeno 1 - 10
of 12
pro vyhledávání: '"HANİFE RAHMANLAR"'
Publikováno v:
Van Tıp Dergisi, Vol 28, Iss 2, Pp 243-248 (2021)
INTRODUCTION: To assess demographic characteristics in patients with ocular Behçet's disease who use off-label drugs in Turkey. METHODS: The applications for off-label drug use (infliximab, adalimumab, mycophenolat mofetil) from hospitals in Turkey
Externí odkaz:
https://doaj.org/article/d9410c9749944098b787fde3235ba69d
Autor:
Şükran Yurtoğulları, Hanife Rahmanlar, Ali Alkan, Banu Bayar, Hakkı Gürsöz, Nurten Uzun Adatepe
Publikováno v:
Türk Nöroloji Dergisi, Vol 26, Iss 3, Pp 235-241 (2020)
Objective: Off-label drug use (OLDU) of neurologic diseases is approved by a regulatory authority, the Turkish Medicines and Medical Devices Agency (TMMDA) in Turkey. It was aimed to investigate the most common neurologic drugs relevant to off-label
Externí odkaz:
https://doaj.org/article/f996d0c6aafa448d9c449e1ae429d7f3
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 8, Iss 2, Pp 249-257 (2020)
Aim:To evaluate the demographic characteristics of patients who use off-label drugs for Age-related Macular Degeneration (AMD) in Turkey.Materials and Methods:The applications for off-label drug use in patients with AMD (bevacizumab, ranibizumab, afl
Externí odkaz:
https://doaj.org/article/73c6a377cd284431a8821aa78128069c
Autor:
Hanife Rahmanlar, Cemile Üçgül Atılgan, Mehmet Çıtırık, İbrahim Muaz Yaradılmış, Hakkı Gürsöz
Publikováno v:
Sakarya Tıp Dergisi, Vol 9, Iss 3, Pp 499-505 (2019)
Amaç: Türkiye’de diyabetik retinopatisi olan hastalarda endikasyon dışı ilaç kullanımı için yapılan başvuruların demografik özelliklerini değerlendirmek. Gereç ve Yöntem: 1 Ocak ile 31 Aralık 2013 tarihleri arasında Türkiye İla
Externí odkaz:
https://doaj.org/article/08868a40724f4ce7b2d238d0a65e81ea
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 47:2101-2106
Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti-vascular endothelial growth factor (anti-VEGF) drugs, ranibizumab and aflibercept, and corticosteroid implants are approved treatment options for RVO-related macular e
Publikováno v:
Romanian journal of ophthalmology. 66(4)
Publikováno v:
European Journal of Hospital Pharmacy. 30:53-56
Objective The use of biological agents in the treatment of ocular Behcet’s disease has recently become more frequent. The use of two agents, infliximab (IFX) and adalimumab (ADA), for the treatment of Behcet’s disease requires prior approval by t
Publikováno v:
Journal of Medicine and Palliative Care. 2:15-20
Amaç: Türkiye’de retinal ven tıkanıklığı (RVT) olan hastalarda endikasyon dışı ilaç kullanımı için yapılan başvuruların demografik özelliklerini değerlendirmek. Gereç ve Yöntem: 1 Ocak ile 31 Aralık 2013 tarihleri arasında T
Publikováno v:
Van Medical Journal. 28:243-248
Publikováno v:
Namık Kemal Tıp Dergisi.